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Neuropilin 1 sequestration by 
neuropathogenic mutant glycyl-
tRNA synthetase is permissive to 
vascular homeostasis
James N. Sleigh  1, Adriana Gómez-Martín1, Na Wei2, Ge Bai2, Xiang-Lei Yang2 &  
Giampietro Schiavo  1,3,4
The mechanism by which dominantly inherited mutations in the housekeeping gene GARS, which 
encodes glycyl-tRNA synthetase (GlyRS), mediate selective peripheral nerve toxicity resulting in 
Charcot-Marie-Tooth disease type 2D (CMT2D) is still largely unresolved. The transmembrane receptor 
protein neuropilin 1 (Nrp1) was recently identified as an aberrant extracellular binding partner of 
mutant GlyRS. Formation of the Nrp1/mutant GlyRS complex antagonises Nrp1 interaction with 
one of its main natural ligands, vascular endothelial growth factor-A (VEGF-A), contributing to 
neurodegeneration. However, reduced extracellular binding of VEGF-A to Nrp1 is known to disrupt 
post-natal blood vessel development and growth. We therefore analysed the vascular system at early 
and late symptomatic time points in CMT2D mouse muscles, retina, and sciatic nerve, as well as in 
embryonic hindbrain. Mutant tissues show no difference in blood vessel diameter, density/growth, and 
branching from embryonic development to three months, spanning the duration over which numerous 
sensory and neuromuscular phenotypes manifest. Our findings indicate that mutant GlyRS-mediated 
disruption of Nrp1/VEGF-A signalling is permissive to maturation and maintenance of the vasculature in 
CMT2D mice.
GARS is a widely and constitutively expressed gene that encodes glycyl-tRNA synthase (GlyRS), which serves to 
covalently attach glycine to its transfer RNA (tRNA), priming it for protein translation1. Dominant mutations 
in GARS cause Charcot-Marie-Tooth disease type 2D (CMT2D, OMIM 601472), a currently incurable disorder 
of the peripheral nerves with the principal clinical symptom of muscle wasting originating in the extremities2. 
A battery of evidence indicates that these GARS mutations cause a toxic, gain-of-function in mutant GlyRS3–8, 
and that this is at least partially reliant upon the surface exposure of protein regions usually buried in wild-type 
GlyRS9. Recently published work suggests that these neomorphic regions cause mutant GlyRS to aberrantly bind 
to the transmembrane receptor neuropilin 1 (Nrp1)10, amongst other proteins8. Nrp1 functions in both the nerv-
ous and vascular systems by modifying multiple signalling pathways11. Mutant GlyRS was shown to specifically 
interact with the extracellular region of Nrp1 integral to VEGF-A165 binding (the b1 domain)12, and thereby 
antagonise Nrp1/VEGF-A signalling (Fig. 1A)10. CMT2D embryonic day 13.5 (E13.5) hindbrains phenocopy the 
facial motor neuron migration defects of mice deficient in VEGF-A164 (murine equivalent of human VEGF-A165) 
or Nrp113. Moreover, genetically reducing Nrp1 levels enhances the severity of CMT2D pathology, whereas pro-
viding additional VEGF-A165, via lentiviral intramuscular injections, improves the phenotype10.
VEGF-A functions in diverse neuronal processes14, 15, and a mild reduction in VEGF-A causes progressive 
motor neuron degeneration in mice16, partially explaining why antagonisation of Nrp1/VEGF-A signalling could 
be contributing to the neuronal pathology in CMT2D10. However, VEGF-A is also critical to blood vessel forma-
tion (vasculogenesis), expansion (angiogenesis), and luminal growth of arteries (arteriogenesis), with the latter 
two processes requiring VEGF-A signalling through Nrp1 and VEGFR217, 18. Nrp1 additionally regulates vascular 
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development by promoting extracellular matrix remodeling downstream of integrins19 and by suppressing exces-
sive TGF-β signalling20. Although mutating the VEGF-A-binding site of Nrp1 does not phenocopy the severity 
of full Nrp1 knockout mice, it causes a post-natal impairment in angiogenesis and arteriogenesis21, 22, resembling 
the milder phenotype of mice expressing VEGF-A isoforms lacking the Nrp1-binding site23. This work suggests 
that Nrp1 has both VEGF-dependent and VEGF-independent functions in blood vessels, and that Nrp1/VEGF-A 
signalling is perhaps more important for vascularisation post- than pre-birth21. Consistent with this, blocking 
VEGF-A binding to Nrp1 with a monoclonal antibody impairs vascular remodeling in the peri-natal mouse 
retina24.
Given that 1) mutant GlyRS competes with VEGF-A for Nrp1 binding10, 2) GlyRS is secreted7, 10, 25 and found 
circulating in serum of humans and mice25, and 3) vascular impairment can contribute to neurodegeneration26, 
we decided to assess the effect of mutant GlyRS on the vascular system of the GarsC201R/+ murine model of 
CMT2D.
Results
GlyRSC157R aberrantly associates with Nrp1. Six different mutations in GARS have been shown to alter 
protein conformation – five CMT2D-associated mutants9 and P234KY corresponding to murine P278KY10, 
which is the spontaneous mutation found in GarsNmf249/+, the more severe CMT2D mouse model4. Neomorphic 
Nrp1 binding and disturbance of Nrp1/VEGF-A signalling has been confirmed for a number of GlyRS mutants, 
including P234KY10. In order to verify a common mechanism in the mild GarsC201R/+ mouse27, we performed 
co-immunoprecipitation assays in NSC-34 cells expressing V5-tagged wild-type, P234KY, L129P, and C157R 
(human equivalent of C201R) GlyRS. GlyRSL129P was included because it is one of the GARS mutants with the best 
evidence linking it to human neuropathy28. As expected, wild-type GlyRS did not bind Nrp1, while GlyRSC157R 
did, albeit at a lower affinity than the other two mutant proteins (Fig. 1B). The intensity of the aberrant interaction 
between mutant GlyRS and Nrp1 thus correlates with the overall severity of the mouse model. These experiments 
confirm that C157R GlyRS spuriously binds to Nrp1 and, extrapolating from findings in the GarsNmf249/+ mouse10, 
suggest that the antagonisation of Nrp1/VEGF-A signalling could contribute to the neuropathic phenotype of 
GarsC201R/+ mice.
Nrp1 is highly expressed in blood vessels of skeletal muscles but not motor neurons. Nrp1 
is widely expressed in a range of different tissues29, localising to the vascular system30, 31 and many neuronal 
types, including motor neurons32–34. As mutated GlyRS binds to Nrp1 impacting the motor nervous system of 
Gars mice10, we examined the expression pattern of Nrp1 in wholemount distal, fast-twitch lumbrical and prox-
imal, slow-twitch transversus abdominis (TVA) muscles from one and three month old wild-type mice. These 
muscles are thin and flat, permitting the visualisation of the entire vascular and nervous systems within the 
tissue35, 36. In these muscles at both time points, Nrp1 (white) did not specifically localise to SV2/2H3+ (green) 
motor neurons or S100+ (blue) Schwann cells (Fig. 2A,B). Rather, its expression consistently coincided with the 
endothelium-binding isolectin B4 (IB4, red) (Figs 2C and S1A,B). Nrp1 could be observed faintly surrounding 
motor neurons, but the staining was wider than that of both S100 (Fig. 2C) and myelin basic protein (Mbp, yel-
low) (Fig. S1C), suggestive of localisation to blood vessels or closely juxtaposed extracellular matrix encasing the 
motor neurons and Schwann cells. These results indicate that Nrp1 predominantly localises to the vascular system 
in post-natal skeletal muscle.
Figure 1. Mutant GlyRS aberrantly binds to the transmembrane receptor neuropilin 1. (A) Schematic of Nrp1 
and one of its principal co-receptors, VEGFR2, which together bind to the secreted glycoprotein VEGF-A165 (on 
the left)11. VEGF-A functions in vasculogenesis, angiogenesis, and arteriogenesis, with the latter two processes 
occurring through Nrp1 and VEGFR2 signalling17, 18. VEGF-A is also critical for nervous system development 
and maintenance15. VEGF-A165 binding to Nrp1 is mainly dependent by the b1 domain12. CMT2D-associated 
mutations in GARS cause a conformational opening of GlyRS, allowing the aberrant binding of mutant GlyRS 
to the b1 domain of Nrp1 (on the right)10. This competitively antagonises Nrp1/VEGF-A signalling, which 
contributes to motor deficits observed in CMT2D mice10. Schematics are not drawn to scale and adapted from 
Plein et al.18 and He et al.10. (B) Co-immunoprecipitation of endogenous Nrp1 showing aberrant interaction 
with P234KY, L129P, and C157R GlyRS (ectopically expressed with a V5-tag) in NSC-34 cells. Wild-type GlyRS 
shows no significant binding to Nrp1. The aberrant interaction is weaker with C157R than with P234KY GlyRS, 
which correlates with the severity of CMT phenotypes in GarsC201R/+ and GarsNmf249/+ mice, respectively.
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Blood vessels in GarsC201R/+ muscle are unaffected. Having shown that C157R mutant GlyRS binds to 
Nrp1 in vitro (Fig. 1B), we assessed structural features of the vascular bed in wild-type and GarsC201R/+ muscles 
using IB4 staining (green, Fig. S2). Confocal Z-stack images were taken throughout the entire depth of one and 
three month old lumbrical and TVA muscles (Fig. 3A,B), and capillary diameter (Fig. 3C,D), density (Fig. 3E,F), 
and branching (Fig. 3G,H) assessed. These time points represent early and late symptomatic stages of disease in 
GarsC201R/+ mice, and were chosen to complement previously performed, in-depth motor and sensory pheno-
typic analyses8, 37. We saw no significant difference between wild-type and mutant Gars capillary beds in any of 
the parameters analysed, suggesting that vasculature is unimpaired in fast and slow twitch skeletal muscles of 
GarsC201R/+ mice. The capillary diameter was consistent across muscles and varied little over time, while capillary 
and branching densities showed variability between muscles, and appeared to decline with age, presumably due 
to muscle growth. These differences confirm the suitability of this strategy for detecting changes in small blood 
vessel structure.
Disruption of VEGF-A binding to Nrp1 has previously been linked with reduced Nrp1 expression in various 
different mouse tissues21. We therefore looked at Nrp1 (white) and VEGFR2 (red) protein levels and localisation 
in lumbrical and TVA muscles, but found no obvious discrepancies between genotypes (Fig. 4A). This was con-
firmed at the mRNA level in disease-susceptible27 tibialis anterior muscles using quantitative RT-PCR (qPCR) 
with either glyceraldehyde 3-phosphate dehydrogenase (Gapdh) or endothelium-specific platelet endothelial cell 
adhesion molecule 1 (Pecam1) as the reference gene (Fig. 4B). Total VEGF-A expression was not significantly 
increased (Fig. 4B). To rule out the possibility that alternative pathways integral to vascular homeostasis may be 
contributing to the maintenance of mutant Gars blood vessel stability, we also assessed the expression of Nrp238, 
Figure 2. Nrp1 localises to skeletal muscle blood vessels but not motor neurons. Representative Nrp1 staining 
in one month old wild-type lumbrical muscles. (A) Nrp1 (white) localises to structures surrounding, but not 
perfectly overlapping, lower motor neurons (SV2/2H3, green), and in SV2/2H3 negative areas. α-bungarotoxin 
(α-BTX, magenta) identifies post-synaptic acetylcholine receptors at the neuromuscular junction. (B) Nrp1 
staining is not wholly contiguous with the Schwann cell marker S100 (blue) either. This was confirmed with 
a second glial cell marker, myelin basic protein (Mbp) in Fig. S1C. (C) Nrp1 co-localises with IB4 (red), an 
endothelial cell marker, indicating that Nrp1 is found in muscle blood vessels. Arrows highlight Nrp1 staining 
associated with motor neurons/myelin, while arrowheads indicate Nrp1+ blood vessels. A similar staining 
pattern was observed at three months and in the TVA muscle at both time points (data not shown). A-B are 
collapsed Z-stack images and C is a single plane image. Scale bars = 20 μm. See also Fig. S1.
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total and soluble VEGFR1 (also known as Flt1 and sFlt1, respectively)14, and genes integral to angiopoietin-Tie 
signalling (Angpt1, Angpt2, Tie1, and Tie2)39. We saw no difference between genotypes in the expression of any of 
these genes (Fig. 4C), indicating that genetic compensation is unlikely to be playing a crucial role in the mainte-
nance of GarsC201R/+ vasculature.
GlyRSC157R/Nrp1 binding is permissive to vascular development and homeostasis. Nrp1 is indis-
pensable for vascularisation of the mouse central nervous system, but is thought to be less critical, although still 
important40, for the vasculature of other tissues such as muscle41. In vivo disruption of VEGF-A binding to Nrp1 
has previously been shown to disturb blood vessel growth and patterning of the mouse retina21, 22. We therefore 
assessed the IB4+ (green) capillary network in one and three month old retinas (Fig. 5A) using an approach simi-
lar to that implemented in the muscle analyses (Fig. 3). Gars mice had similar retinal capillary diameters (Fig. 5B), 
densities (Fig. 5C), and branching (Fig. 5D) as wild-type animals at both time points. There was also no difference 
in the number of major radial branches (arteries and veins) emanating from the central retina (Fig. 5E). Similar to 
skeletal muscles, no obvious differences in Nrp1 and VEGFR2 staining were seen in mutant Gars retinas at either 
time point (data not shown).
At post-natal day 6–9 (P6-9), vascular extension and artery number are reduced in mice carrying a knockin 
Nrp1 mutation that abrogates VEGF-A binding21, 22, 42. By adulthood, vascular extension has recovered, but 
Figure 3. Capillaries appear unaffected in GarsC201R/+ skeletal muscles. (A,B) Representative single plane (A, 
top) and collapsed Z-stack (A, bottom and B) images of IB4 (green) staining in one month lumbrical (A) and 
TVA muscles (B). Scale bars = 1 mm (A, top) and 20 μm (A, bottom and B). (C,E,G) No defects in capillary 
diameter (C, age, P = 0.007; genotype, P = 0.090; interaction, P = 0.508), density (E, age, P < 0.001; genotype, 
P = 0.290; interaction, P = 0.625), or branching density (F, age, P < 0.001; genotype, P = 0.468; interaction, 
P = 0.721) were observed in GarsC201R/+ mouse lumbrical muscles at one or three months. (D,F,H) The TVA 
muscle also showed no difference in capillary diameter (D, age, P = 0.875; genotype, P = 0.264; interaction, 
P = 0.359), density (F, age, P < 0.001; genotype, P = 0.223; interaction, P = 0.889), or branching density (H, 
age, P = 0.020; genotype, P = 0.086; interaction, P = 0.340). All data sets were analysed with two-way ANOVAs. 
n = 5. See also Fig. S2.
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artery number remains diminished21, 22. To determine whether mutant GlyRS binding to Nrp1 causes similar 
nascent phenotypes, we dissected retinas from P6-7 wild-type and GarsC201R/+ mice and stained them with IB4 
(green, Fig. 5F-i) and a fluorophore-conjugated antibody against α smooth muscle actin (αSMA, red, Fig. 5F-ii), 
an artery-specific marker. Wild-type and mutant Gars retinas showed similar vascular extension (Fig. 5G). 
Furthermore, there was no difference in the number of retinal arteries between genotypes (Fig. 5H), which is 
consistent with the major radial branch analysis at one month (Fig. 5E).
Fly and mouse models of CMT2D display early developmental defects in the nervous system7, 8, 10. We 
therefore assessed parameters of the capillary network in E13.5 hindbrains of wild-type and GarsC201R/+ mice. 
Mutant brains showed no differences in blood vessel structures between genotypes (Fig. 6A,C–E), nor in Nrp1 
Figure 4. Pathways integral to vascular homeostasis appear unperturbed in mutant Gars muscle.  
(A) Representative Nrp1 (white) and VEGFR2 (red) staining in one month old wholemount wild-type and 
GarsC201R/+ TVA muscles. Nrp1 and VEGFR2 colocalise with the endothelial marker IB4 (green) in both 
genotypes, and show no obvious differences. A similar pattern was seen at three months and in the lumbrical 
muscles at both time points (data not shown). Both panels are single plane images. Scale bars = 200 μm.  
(B,C) qPCR analysis of a series of genes integral to the maintenance of blood vessels indicates very little 
perturbation in gene expression in one month GarsC201R/+ tibialis anterior muscles. This was confirmed using 
either Gapdh (top graphs) or endothelium-specific Pecam1 (bottom graphs) as the reference gene. All individual 
gene data sets were separately analysed with unpaired, two-tailed t-tests. n = 6 wild-type and 4 GarsC201R/+.
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and VEGFR2 staining (data not shown), which is consistent with western blotting data showing that Nrp1 and 
VEGFR2 protein levels remain unaltered in embryonic Gars neural tissues10. This lack of an embryonic vascular 
phenotype mirrors the result in mice with deficient VEGF-A binding to Nrp122. Finally, we assessed vascular 
density in sectioned sciatic nerves from one month old mice, in order to determine whether post-natal neuronal 
tissue was perturbed. Anti-Pecam1 (green) was used instead of IB4 due to superior staining of the vasculature in 
this tissue (Fig. 6B). Mutant mice showed a non-significant trend towards increased capillary density (Fig. 6F); 
however, this might simply be caused by the reduced axon calibres (without axon loss) of mutant mice27, i.e. the 
capillaries command a greater percentage area of the sciatic nerve due to the axons being smaller.
Discussion
Mutant GlyRS appears to compete with VEGF-A for extracellular binding to the transmembrane receptor pro-
tein Nrp1 contributing to the peripheral nerve pathology observed in CMT2D10. Reduced binding of VEGF-A 
to Nrp1 has previously been shown to impair post-natal angiogenesis and arteriogenesis21, 22. We thus set out 
to determine whether the capillary network of mutant Gars mice is altered either in the post-natal period or 
Figure 5. The blood vessel network is unperturbed in GarsC201R/+ retinas. (A) Representative single plane (top) 
and collapsed Z-stack (bottom) images of IB4 (green) staining in one month retina. Scale bars = 1 mm (top) 
and 20 μm (bottom). (B–E) No defects in capillary diameter (B, age, P = 0.823; genotype, P = 0.112; interaction, 
P = 0.105), density (C, age, P = 0.878; genotype, P = 0.638; interaction, P = 0.504), branching density (D, age, 
P = 0.042; genotype, P = 0.548; interaction, P = 0.345), or major radial branch (arteries and veins, arrow in A) 
number (E, age, P = 0.541; genotype, P = 0.395; interaction, P = 0.188) were observed in GarsC201R/+ mouse 
retinas at one or three months. n = 5. (F) Representative single plane images of IB4 (i) and αSMA (red, ii) 
staining in P6-7 retina. Letters a and b (i) indicate how vascular extension was assessed (a /a + b) and the 
arrowhead (ii) highlights an αSMA+ artery. Scale bars = 1 mm. (G,H) There is no difference in IB4+ vascular 
extension (G, P = 0.818) or αSMA+ artery number (H, P = 0.967) between wild-type and GarsC201R/+ P6-7 
retinas. n = 3 wild-type and 5 GarsC201R/+. Data sets were analysed with either a two-way ANOVA (B–E) or an 
unpaired, two-tailed t-test (G,H). See also Fig. S2.
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during development. First, we confirmed that the human orthologue of murine GlyRSC201R (GlyRSC157R), but not 
wild-type, was capable of aberrantly binding to Nrp1 (Fig. 1B). This interaction is weaker than for GlyRSP234KY, 
which is expressed in GarsNm249/+ mice, indicating that mutant disease severity correlates with neomorphic bind-
ing affinity. We then found that Nrp1 was highly expressed in post-natal skeletal muscle blood vessels, but not in 
motor neurons (Fig. 2); in spite of previously published results43. This discrepancy may be due low Nrp1 abun-
dance in motor neurons compared to blood vessels and/or differential Nrp1 expression between muscle types 
(e.g. gastrocnemius versus TVA and lumbricals).
The fundamental requirement for Nrp1 in motor nervous system development is undisputed32–34, 44, but its 
post-natal function and localisation remains less well defined. Motor neuron-specific ablation of Nrp1 using 
the Olig2 promoter is reported to cause post-natal motor axon loss and muscle atrophy45, but Nrp1 was deleted 
developmentally46 rather than at or post-birth. It is possible that low levels of post-natal Nrp1 expression in motor 
neurons allows aberrant mutant GlyRS binding and signalling sufficient to drive peripheral nerve degeneration in 
CMT2D mice. However, given that embryonic defects are observed in Gars mice8, 10, and that Nrp1 expression is 
developmentally downregulated in neuronal tissue47, 48, we should not rule out that mutant GlyRS-mediated inhi-
bition of Nrp1/VEGF-A signalling during development may be predisposing the motor system to the subsequent 
degeneration observed at later, post-natal stages37, 49.
Given the high levels of Nrp1 expression present in the vasculature of skeletal muscles (Fig. 2), and previ-
ously reported in retinas and embryonic hindbrains30, 31, we decided to assess capillary architecture in a range of 
tissues covering the developmental to late symptomatic period. Capillary diameter, density, and branching were 
unaltered by mutant GlyRS in both distal and proximal skeletal muscles (Fig. 3), as was expression of numerous 
genes that play a key role in vascular homeostasis (Fig. 4). Lack of a vascular phenotype was replicated in adult 
retinas (Fig. 5A–E), one month sciatic nerves (Fig. 6F), and embryonic hindbrains (Fig. 6C–E), while P6-9 retinal 
defects caused by mutating the VEGF-A binding site of Nrp121, 22 were also not present in mutant Gars vasculature 
(Fig. 5F–H). We have therefore shown that the vascular system is unaffected in GarsC201R/+ mice from embry-
onic development to adulthood. Extra-neuronal tissue pathology and disease mechanisms have been reported 
in mouse models of several peripheral nerve conditions including spinal muscular atrophy50, Kennedy’s dis-
ease51, 52, and amyotrophic lateral sclerosis53, appearing to mirror the human conditions, at least in some of their 
most debilitating incarnations54. Nevertheless, we have convincingly ruled out that vascular pathology extends to 
CMT2D, which is in keeping with the clinical presentation of patients.
So why does antagonising Nrp1/VEGF-A signalling affect the peripheral nervous system, but not the vas-
cular system, when this pathway is vital for the functioning of both? First of all, timing and location of Nrp1 
and GlyRS expression could conspire to ensure neuronal specificity. GlyRS is secreted and present in serum, 
but it may not be found in proximity of Nrp1 on blood vessels. For instance, if GlyRS is secreted by terminal 
Schwann cells at the neuromuscular synapse, mutant GlyRS may only gain access to Nrp1 on motor nerve ter-
minals. Alternatively, the lack of a Gars vascular phenotype may reflect that blood vessels require lower levels of 
Nrp1/VEGF-A signalling than neurons. Finally, mutant GlyRS may be competing with VEGF-A for Nrp1 binding 
and simply impinging upon VEGF-A-initiated signalling events integral to the nervous, but not vascular, system. 
Given that VEGF-A is capable of regulating the two vascular-specific processes of angiogenesis and arteriogenesis 
Figure 6. Gars mutant embryonic hindbrains and sciatic nerves show no vascular defects. (A,B) Representative 
single plane (A, top and B) and collapsed Z-stack (A, bottom) images of IB4 and Pecam1 staining (green) 
in E13.5 hindbrain (A) and one month sciatic nerve (B), respectively. Scale bars = 1 mm (A, top) and 20 μm 
(A, bottom, and B). (C–E) Capillary diameter (C, P = 0.593), density (D, P = 0.456), and branching density 
(E, P = 0.278) are all unimpaired in GarsC201R/+ E13.5 hindbrains. n = 9 wild-type and 5 GarsC201R/+. (F) 
Mutant sciatic nerves show no difference in capillary density at one month (P = 0.111). n = 4 wild-type and 5 
GarsC201R/+. All data were analysed with unpaired, two-tailed t-tests. See also Fig. S2.
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via distinct pathways40, this latter scenario is highly conceivable. Indeed, it is corroborated by the previous obser-
vation that VEGF-A-deficient mice display selective degeneration of motor neurons16.
In summary, we have demonstrated that CMT2D mice display a pathological phenotype restricted to the 
nervous system, and that GlyRS-mediated disruption of Nrp1/VEGF-A signalling appears to be permissive to 
capillary maturation and maintenance. This is consistent with mutant GlyRS binding to Nrp1 affecting a nervous 
system-specific function of the Nrp1/VEGF-A pathway.
Materials and Methods
NSC-34 cell culture and transfection. NSC-34 cell line was purchased from ATCC (Manassas, VA) and 
grown in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher, Waltham, MA, 41966) supplemented 
with 10% (v/v) fetal bovine serum (Omega Scientific, Singapore) and 1% (v/v) penicillin-streptomycin (Thermo 
Fisher, 15140148). Cells were split every two to three days using 0.25% (v/v) trypsin-EDTA (Thermo Fisher, 
25200) and cultures maintained at 37 °C in a 5% (v/v) CO2 humidified atmosphere. For transfection, NSC-34 
cells were grown to ≈70% confluency. Human wild-type, P234KY, L129P, or C157R GARS gene was inserted into 
pcDNA6 plasmid to express wild-type or mutant GlyRS with a V5 tag in NSC-34 cells. Cells were transfected 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 116680) according to the manufacturer’s instruction.
Co-immunoprecipitation and western blotting. For cell lysate preparation, 36 h post-transfection 
NSC-34 cells were washed twice in phosphate-buffered saline (PBS, 137 mM NaCl, 10 mM Na2HPO4, 2.7 mM 
KCl, 1.8 mM KH2PO4), scraped into PBS, pelleted, re-suspended in Pierce IP Lysis Buffer (Thermo Fisher, 87787) 
for 30 min, and the extract cleared for 7 min at 12,000 × g. Protein G beads (Invitrogen) were pre-incubated with 
rabbit anti-Nrp1 (Abcam, Cambridge, UK, ab81321) or rabbit IgG (Cell Signaling Technology, Danvers, MA) for 
30 min before mixing with cell lysates overnight. The beads were then washed three times with buffer (100 mM 
NaCl, 50 mM Tris-HCl, pH 7.5, 0.1% (v/v) Triton X-100, 5% (v/v) glycerol), and immunoprecipitates probed by 
western blot. Immunoprecipitates were fractionated by 4-12% (v/v) Bis-Tris-Plus SDS-PAGE gels (Invitrogen) 
and transferred to PVDF membranes using the iBlot Dry Blotting System (Invitrogen). Membranes were blocked 
for 1 h with Tris-buffered saline with 0.1% (v/v) Tween 20 containing 5% (w/v) non-fat dry milk. Wild-type 
and mutant GlyRS proteins were detected using mouse anti-V5 (1/3000, Invitrogen, R960CUS) and Nrp1 using 
the same antibody as for co-immunoprecipitation (1/1000). After primary antibody incubation, membranes 
were washed and probed with HRP-conjugated anti-mouse or anti-rabbit secondary antibodies (Cell Signaling 
Technology), followed by detection using ECL western blotting substrate (Thermo Fisher) using the FluorChem 
M imager (ProteinSimple, San Jose, CA).
Animals. GarsC201R/+ mice were maintained as heterozygote breeding pairs on a predominantly C57BL/6 
background and genotyped as described previously27. Mice sacrificed at one and three month time points were 
28–34 and 89–97 days old, respectively. Multiple tissues were simultaneously harvested from both males and 
females. Mouse handling and experiments were performed under license from the UK Home Office in accord-
ance with the Animals (Scientific Procedures) Act (1986), and approved by the University College London (UCL) 
– Institute of Neurology Ethics Committee.
Tissue preparation and immunohistochemistry. All steps were performed at room temperature, apart 
from overnight incubations conducted at 4 °C. Lumbrical and TVA muscles were dissected and immunohisto-
chemically labelled as previously described35–37. Eyes were removed and fixed in 4% (w/v) paraformaldehyde 
(PFA, Electron Microscopy Sciences, Hatfield, PA) for 2 h, before retinas were dissected and stained as reported 
previously55. Sciatic nerves were dissected from mice transcardially perfused with 4% PFA, post-fixed for 2 h, and 
10 μm sections processed and stained as previously described8. E13.5 hindbrains were dissected and stained using 
published protocols56.
Gene Ensembl ID Forward Primer (5′-3′) Reverse Primer (5′-3′)
Angpt1 ENSMUSG00000022309 GCT GAC AGA TGT TGA GAC C TGT CTG TTG GAG AAG TTG C
Angpt2 ENSMUSG00000031465 AGT CCA ACT ACA GGA TTC ACC TGT CCG AAT CCT TTG TGC
Gapdh ENSMUSG00000057666 TGT GTC CGT CGT GGA TCT GA58 CCT GCT TCA CCA CCT TCT TGA58
Nrp1 ENSMUSG00000025810 GGC TGT GAA GTG GAA GCA CC AGT GGT GCC TCC TGT GAG C
Nrp2 ENSMUSG00000025969 CCG CAC GTT ACT ATT TGA TCC TCA GAG AAG GTG GAG GAG G
Pecam1 ENSMUSG00000020717 ATT GAG GCG CAG GAC CAC G AAG GAC TCC TGC ACG GTG ACG
Tie1 ENSMUSG00000033191 GGG AGA TAG TGA GCC TTG G CTC GTA CAC TTC GTC ATC G
Tie2 (Tek) ENSMUSG00000006386 CAC CGA GGC TAT TTG TAC C CTG TAC TGT TGG CGA TGG
VEGF-A ENSMUSG00000023951 CAT GCC AAG TGG TCC CAG G CTC AAT CGG ACG GCA GTA GC
VEGFR1 (Flt1) ENSMUSG00000029648 TAT GCG TGC AGA GCC AGG GCC ACT GAT GGA GAC CTC G
sVEGFR1 (sFlt1) ENSMUSG00000029648 TAT GCG TGC AGA GCC AGG TCC GAG AGA AAA TGG CCT TTT59
VEGFR2 (Kdr) ENSMUSG00000062960 TCT TTG CGC TAG GTA TCC CTC ACA GAA GAC CAT GCC
Table 1. Primers used for qPCR analysis. Angpt1/2, angiopoietin 1/2; Gapdh, glyceraldehyde 3-phosphate 
dehydrogenase; Nrp1/2, neuropilin 1/2; Pecam1, platelet endothelial cell adhesion molecule 1; Tie1/2, tyrosine 
kinase with immunoglobulin-like and EGF-like domains 1/2; VEGF-A, vascular endothelial growth factor A; 
VEGFR1/2, vascular endothelial growth factor receptor 1/2; sVEGFR1, soluble VEGFR1.
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The following primary antibodies were used for immunofluorescence studies: mouse anti-Mbp (1/250, 
Boehringer, Ingelheim am Rhein, Germany, 1118099), mouse anti-neurofilament (1/50, 2H3, Developmental 
Studies Hybridoma Bank [DSHB], Iowa City, IA, supernatant), goat anti-Nrp1 (1/100, R & D Systems, 
Minneapolis, MN, AF566), goat anti-Pecam1 (1/50, Santa Cruz Biotechnology, Dallas, TX, sc-1506), rabbit 
anti-S100 (1/200, Dako, Glostrup Municipality, Denmark, Z0311), mouse pan anti-synaptic vesicle 2 (1/100, 
SV2, DSHB, concentrate), and rabbit anti-VEGFR2 (1/100, Cell Signaling Technology, 55B11). When appro-
priate, tissues were also incubated with 1 mg/ml IB4 biotin conjugate (Sigma Aldrich, St. Louis, MO, L2140) in 
PBS at 1/50 (retinas) or 1/250 (all other tissues). The following day, combinations of Alexa Fluor-labelled sec-
ondary antibodies (Life Technologies, Carlsbad, CA, A-21202, A-21432, A-21447, A-31570, A-31572) at 1/250, 
2 mg/ml streptavidin Alexa Fluor 488 conjugate (Life Technologies, S-11223) at 1/250, fluorophore-conjugated 
α-bungarotoxin (α-BTX, Life Technologies, B-13422 and B-35451; Biotium, Fremont, CA, 00002) at 1/1000, and 
Cy3-conjugated anti-αSMA (Sigma, C6198) at 1/500 in PBS were used for 2 h, before the tissues were washed and 
mounted in fluorescent mounting medium (Dako, S3023) for imaging.
Imaging and analysis. Tissues were imaged using a LSM 780 laser scanning microscope (Zeiss, 
Oberkochen, Germany) and images analysed using ImageJ software (https://imagej.nih.gov/ij/). All samples were 
imaged and analysed blinded to genotype. No samples were excluded from the analyses once imaged. IB4-stained 
muscles, retinas, and hindbrains, and Pecam1-stained sciatic nerve sections were used for capillary analyses as 
performed previously54, 57. Maximal Z-resolution stacked images across the entire depth of wholemount tissues 
were obtained at 40x (for muscles) and 20x (for retinas and hindbrains) magnification and 1024 × 1024 pixel 
resolution. Sciatic nerve sections were single plane images taken at 20x and 2812 × 2812 pixel resolution. Three 
non-overlapping fields of view were imaged per lumbrical muscle, and four lumbricals analysed per animal (12 
Z-stacks in total). Eight non-redundant Z-stack images were obtained per TVA and retina, and four per hind-
brain, and analysed for each animal. Similar tissue regions were imaged across samples. Five different sections 
were analysed per sciatic nerve. For measuring capillary diameters, a uniform grid (area per point: 500 μm2) was 
overlaid onto 3D-projected (Max Intensity) images, and every capillary found at a grid intersection measured 
(except those that were branching), with repeated measures of the same capillary accepted (Fig. S2A,B). Over 400 
capillary diameters were measured and averaged per tissue per genotype. For capillary density analyses, images 
were 3D-projected (Max Intensity), converted to binary (capillaries assigned to black), and particles analysed 
(Fig. S2A,C). The summed black particle number was then divided by the number of sections to account for 
Z-stack depth. To assess branching density, capillary bifurcations were counted using the Cell Counter plugin on 
projected images and the total branches divided by the number of sections (Fig. S2A,D). Non-projected image 
stacks were used to ensure the counted branches were bifurcations and not crossing capillaries. Vascular exten-
sion was assessed in P6-7 retinas by calculating the percentage growth of IB4+ vasculature from the centre to the 
edge of the retina (a/a + b, Fig. 5F-i). To restrict the impact of minor differences in developmental stage between 
litters, individual extension percentages were normalised to the wild-type mean within the litter.
RNA extraction and qPCR. Tibialis anterior muscles were dissected from one month old wild-type and 
GarsC201R/+ mice, and RNA extracted using an RNeasy Micro Kit (QIAGEN, Hilden, Germany, 74004) as per the 
manufacturer’s instructions. SuperScript IV (Invitrogen, 18090050) was used as instructed to reverse transcribe 
1 μg RNA. Copy DNA was diluted in water (1/10), before qPCR analyses were performed using PowerUp SYBR 
Green (Applied Biosystems, Foster City, CA, A25742) and a CFX96 Real-Time System (Bio-Rad, Hercules, CA) 
as previously described58. Cycling conditions were as follows: 50 °C for 2 min, 95 °C for 2 min, 40x [95 °C for 3 s, 
60 °C for 30 s]. Primers were used at 500 nm and their sequences are detailed in Table 1.
Statistical analysis. Data were assumed to be normally distributed unless evidence to the contrary was 
provided by the D’Agostino and Pearson omnibus normality test. GraphPad Prism 5 (La Jolla, CA) was used for 
all analyses. Means ± standard error of the mean are plotted, except for individual capillary diameter data, which 
represent mean and standard deviation. All analyses were performed on animal mean values.
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